SREBF1 and Insulin resistance: In the present study, ipragliflozin attenuated hyperinsulinemia probably via improving hyperglycemia in obese mice with insulin resistance, associated with reduced gene expression of de novo lipogenesis including Srebp1c and Acc1 in the liver.